| Literature DB >> 25477884 |
Abstract
Understanding the regulation of antibody production and B-cell memory formation and function is core to finding new treatments for B-cell-derived cancers, antibody-mediated autoimmune disorders, and immunodeficiencies. Progression from a small number of antigen-specific B-cells to the production of a large number of antibody-secreting cells is tightly regulated. Although much progress has been made in revealing the transcriptional regulation of B-cell differentiation that occurs during humoral immune responses, there are still many questions that remain unanswered. Recent work on the expression and roles of histone modifiers in lymphocytes has begun to shed light on this additional level of regulation. This review will discuss the recent advancements in understanding how humoral immune responses, in particular germinal centers and memory cells, are modulated by histone modifiers.Entities:
Keywords: B-cells; EZH2; MOZ; epigenetics; germinal centers; histone modifiers; humoral memory
Year: 2014 PMID: 25477884 PMCID: PMC4237133 DOI: 10.3389/fimmu.2014.00596
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Histone modifications that may regulate B-cell differentiation. (A) B-cell differentiation during a T-dependent humoral response. Naïve B-cells that are specific to a foreign pathogen will become activated and receive help from accessory cells. They may become early memory B-cells or extrafollicular plasmablasts, or form a GC. GC B-cells then may either differentiate into long-lived plasma cells or memory B-cells. Within the memory population, there are IgM and IgG memory B-cells. Histone marks in naïve and activated B-cells are noted (15). (B,C) Phenotypes of EZH2-deficient (B) and MOZ-deficient (C) mice after immunization.
Humoral responses in the absence of EZH2, MOZ, p300 (acetyltransferase activity), or DNMT1 [from Ref. (.
| Deletion | Type (target) | GC response | Memory | Plasma cells/Antibody |
|---|---|---|---|---|
| EZH2 | Methyltransferase (H3K27) | – Absent – Reduction in proliferative cells – Higher frequency of cells in G0/G1 – Increase in apoptosis | Decreased IgG1+ memory and affinity | – Decreased IgG1, IgG2b – No change in IgG2a or IgG3 – Decreased plasma cells in vivo – Increased plasmablasts in vitro |
| MOZ | Acetyltransferase (H3K9) | – Decreased – Dark zone GC B-cells reduced Higher frequency of cells in G0/G1 Decreased BCL-6 | – Numbers of IgG1+ memory normal but decreased affinity – Increased IgM+ memory | – No change in numbers, but decrease in affinity of plasma cells |
| p300AT | Acetyltransferase | No change | – Memory response impaired | – No change in IgG1 – IgG2b decreased – SLE-like disease |
| DNMT1 | Methyltransferase (DNA) | – Decreased – Reduction in proliferative cells | Not assessed | Not assessed |